Albany Molecular Research (AMRI) Misses Q1 EPS by 14c

Go back to Albany Molecular Research (AMRI) Misses Q1 EPS by 14c

AMRI Announces First Quarter 2016 Results

May 10, 2016 7:35 AM EDT

ALBANY, N.Y., May 10, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2016 and provided an update to its outlook for 2016.

Highlights:

First quarter contract revenue of $102.8 million, up 37% from 2015 First quarter royalties of $2.7 million, down 59% from 2015 due to expiration of Allegra royalties in Q2-2015 First quarter adjusted contract margins 27% First quarter adjusted diluted EPS of $0.07, reflecting a $0.07 decrease in EPS from royalties in the current quarter First... More

AMRI Appoints Louis Yu, Ph.D., as Senior Vice President, Quality and Compliance

May 9, 2016 8:00 AM EDT

ALBANY, N.Y., May 9, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has hired Louis Yu, Ph.D., to fill the newly created position of senior vice president of quality and compliance. Dr. Yu will report to William S. Marth, AMRI's president and CEO. Dr. Yu will oversee all aspects of quality and cGMP compliance at all divisions of AMRI, including Drug Discovery Services, API and Drug Product development and manufacturing.

"AMRI has an outstanding reputation for quality service, and as we continue to expand our... More